摘要
目的急性重症胰腺炎患者通过奥曲肽与乌司他丁进行联合治疗,研究患者所得到的临床疗效以及安全性。方法随机从该院在2018年1月—2019年1月期间收治的急性重症胰腺炎患者中挑选出60例患者,按照使用药物的方法的不同进行分组,两组均由30例患者所构成,对照组患者只通过使用奥曲肽进行治疗,观察组在对照组患者的基础上,外加使用乌司他丁,对两组患者的资料总有效率以及不良反应的发生率进行比较,从而分析两者联合的临床疗效以及安全性情况。结果观察组患者得到的治疗总有效率为93.3%(28/30),其中康复患者有16例,效果显著患者有8例,产生一定效果的患者有4例,没有产生效果的患者有2例,对照组患者得到的治疗总有效率为76.7%(23/30),其中康复患者有8例,效果显著患者有6例,产生一定效果的患者有9例,没有产生效果的患者有7例,组间差异有统计学意义(χ^2=15.984,P<0.05);观察组患者的不良反应发生情况为1例患者发生轻微腹胀,1例患者发生头晕乏力,发生率为6.7%,对照组患者的不良反应发生情况为:2例患者发生恶心呕吐,2例患者发生头晕乏力,3例患者发生轻微腹胀,发生率为23.3%(7/30),组间差异有统计学意义(χ^2=15.439,P<0.05)。结论利用奥曲肽与乌司他丁联合治疗急性重症胰腺炎患者,患者可以取得显著的治疗效果,不良反应发生率低,具有较高的安全性,值得在临床中推广以及应用。
Objective To treat patients with acute severe pancreatitis by combining octreotide with ulinastatin to study the clinical efficacy and safety of patients.Methods Sixty patients were randomly selected from patients with acute severe pancreatitis admitted to the hospital from January 2018 to January 2019.Grouped according to the method of drug use,30 patients in each group were included.The control group was treated only with octreotide.The observation group was compared with the control group added ulinastatin.The total effective rate and the incidence of adverse reactions were compared between the two groups.Analyze the combined clinical efficacy and safety of the two.Results The total effective rate of treatment in the observation group was 93.3%(28/30),including 16 patients with rehabilitation,8 patients with significant effects,4 patients with certain effects,and 2 patients without effect.For example,the total effective rate of treatment in the control group was 76.7%(23/30),including 8 patients with rehabilitation,6 patients with significant effects,9 patients with certain effects,and 7 patients without effect.the difference was statistically significant(χ^2=15.984,P<0.05),The adverse reactions in the observation group were:1 case of mild abdominal distension,1 case of dizziness and fatigue,incidence of 6.7%,the adverse reactions in the control group were:nausea and vomiting in 2 patients,dizziness and weakness in 2 patients,and mild bloating in 3 patients,the incidence was 23.3%(7/30),the difference was statistically significant(χ^2=15.439,P<0.05)Conclusion The combination of octreotide and ulinastatin in the treatment of patients with acute severe pancreatitis can achieve significant therapeutic effects,low incidence of adverse reactions,and high safety.It is worthy of promotion and application in the clinic.
作者
向睿
XIANG Rui(Department of Critical Care Medicine,People's Hospital of Hechuan District,Chongqing,401520 China)
出处
《系统医学》
2020年第1期83-85,共3页
Systems Medicine
关键词
奥曲肽
乌司他丁
急性重症胰腺炎
临床疗效
Octreotide
Ulinastatin
Acute severe pancreatitis
Clinical efficacy
